Separately, BTIG Research decreased their target price on Humacyte to $9.00 in a research report on Thursday, October 20th.
Humacyte Stock Down 1.5 %
Shares of HUMA stock opened at $3.21 on Thursday. Humacyte has a 1 year low of $3.02 and a 1 year high of $12.22. The stock has a market cap of $330.65 million, a PE ratio of 10.03 and a beta of 1.01. The business’s fifty day moving average is $3.55 and its 200-day moving average is $4.07. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.46 and a current ratio of 17.46.
Insider Transactions at Humacyte
In other news, Director Brady W. Dougan sold 1,522,500 shares of the firm’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $4.00, for a total value of $6,090,000.00. Following the completion of the sale, the director now owns 18,930,004 shares of the company’s stock, valued at $75,720,016. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 25.00% of the stock is currently owned by insiders.
Institutional Trading of Humacyte
A number of institutional investors have recently bought and sold shares of the company. UBS Group AG boosted its position in Humacyte by 92.0% during the third quarter. UBS Group AG now owns 9,827 shares of the company’s stock valued at $32,000 after purchasing an additional 4,710 shares during the last quarter. Hamilton Lane Advisors LLC acquired a new stake in Humacyte during the third quarter valued at $172,000. Teacher Retirement System of Texas acquired a new stake in Humacyte during the third quarter valued at $60,000. SG Americas Securities LLC acquired a new stake in Humacyte during the third quarter valued at $35,000. Finally, Legal & General Group Plc boosted its position in Humacyte by 24.7% during the second quarter. Legal & General Group Plc now owns 16,970 shares of the company’s stock valued at $55,000 after purchasing an additional 3,364 shares during the last quarter. Institutional investors and hedge funds own 13.05% of the company’s stock.
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).
- Get a free copy of the StockNews.com research report on Humacyte (HUMA)
- Alphabet Stock Offers a Rare Buying Opportunity
- Walt Disney Stock is Set to Reset Expectations
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.